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Abstract
Context: Placenta-derived circulating factors contribute to the maternal endothelial dysfunction underlying preeclampsia.
Endothelial colony forming cells (ECFC), a sub-population of endothelial progenitor cells (EPCs), are thought to be involved
in vasculogenesis and endothelial repair. Low vitamin D concentrations are associated with an increased risk for
preeclampsia.
Objective: We hypothesized that the function of human fetal ECFCs in culture would be suppressed by exposure to
preeclampsia-related factors–preeclampsia serum or hypoxic placental conditioned medium– in a fashion reversed by
vitamin D.
Design, Setting, Patients: ECFCs were isolated from cord blood of uncomplicated pregnancies and expanded in culture.
Uncomplicated pregnancy villous placenta in explant culture were exposed to either 2% (hypoxic), 8% (normoxic) or 21%
(hyperoxic) O2 for 48 h, after which the conditioned media (CM) was collected.
Outcome Measures: ECFC tubule formation (Matrigel assay) and migration were examined in the presence of either
maternal serum from preeclampsia cases or uncomplicated pregnancy controls, or pooled CM, in the presence or absence
of 1,25(OH)2 vitamin D3.
Results: 1,25(OH)2 vitamin D3 reversed the adverse effects of preeclampsia serum or CM from hypoxic placenta on ECFCs
capillary-tube formation and migration. Silencing of VDR expression by VDR siRNA, VDR blockade, or VEGF pathway
blockade reduced ECFC functional abilities. Effects of VDR or VEGF blockade were partially prevented by vitamin D.
Conclusion: Vitamin D promotes the capillary-like tubule formation and migration of ECFCs in culture, minimizing the
negative effects of exposure to preeclampsia-related factors. Further evaluation of the role of vitamin D in ECFC regulation
and preeclampsia is warranted.
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Introduction
Preeclampsia remains one of the most common causes of
maternal and fetal morbidity and mortality in the developed world
[1–3]. Although the pathogenesis of preeclampsia is still not fully
understood, a multi-stage model is generally accepted. The utero-
placental syndrome with impaired placental development in the
first stage of the disease causes generalized maternal endothelial
dysfunction as a main clinical feature of preeclampsia in the
second stage [4]. An array of placenta-derived factors are
candidate contributors to endothelial dysfunction in preeclampsia
[5–7].
Endothelial progenitor cells (EPCs) are believed to play an
important role in vascular homeostasis and in the repair of injured
endothelium and neovascularization [8]. EPCs participate in both
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wound healing and angiogenesis. Decreased cell numbers of
hematopoietic EPCs in the maternal circulation have been
described as a potential sign of impaired endothelial repair
capacity in preeclampsia [9,10]. The late outgrowth sub-popula-
tion of EPCs, also referred to as ‘‘endothelial colony forming cells’’
(ECFCs), have true endothelial-like characteristics, unlike the
hematopoietic EPCs studied in the context of preeclampsia
previously [11]. ECFCs are highly proliferative and migrate to
sites of vessel formation, possessing the ability to differentiate into
mature endothelial cells, to participate in vessel repair and to form
de novo endothelium [12]. Recent data suggest that fetal ECFCs
posses the ability to cross the placenta and participate in de novo
maternal vessel formation in the pregnant uterus [13].
Vitamin D deficiency may be a risk factor for developing
preeclampsia [14–18]. However, the underlying mechanisms are
unclear. Our previous data suggest a VEGF dependent effect of
vitamin D on ECFC proliferation and angiogenesis capability
[19]. Given that the nature of the endothelial cell dysfunction and
the role of ECFCs in preeclampsia are not entirely clear, we
undertook this study in order to explore the effects of potentially
relevant factors, i.e. serum from preeclamptic women or condi-
tioned medium from placental villous explants exposed to hypoxic
(2% O2) and hyperoxic (21%) oxygen tension, on ECFC function.
In addition, we aimed to investigate whether the addition of
1,25(OH)2 vitamin D3 to the culture media can prevent ECFC
dysfunction under these conditions.
Materials and Methods
This collaborative study was performed at Magee-Womens
Research Institute, Pittsburgh, PA and at the Department of
Obstetrics and Gynecology, Hannover Medical School, Germany.
The University of Pittsburgh Institutional Review Board and the
Ethical Committee at Hannover Medical School approved the
study and informed written consent was obtained from each
woman.
Patient Blood Sample Collection
Twelve healthy women with uncomplicated, normotensive
pregnancies (controls) and 12 women with preeclampsia provided
pre-delivery maternal blood samples for our study, 6 of each group
being primiparous and 6 multiparous. All had singleton pregnan-
cies. Clinical and demographic data describing these pregnant
subjects, all of whom delivered at Magee-Womens Hospital, are
presented in Table 1. Patients were matched for gestational age at
the time of blood sampling, body mass index (BMI) and race.
Patients with preeclampsia had gestational hypertension and
proteinuria beginning after 20 weeks of pregnancy with resolution
of clinical symptoms postpartum. Gestational hypertension was
recognized as an absolute blood pressure $140 mmHg systolic
and/or $90 mmHg diastolic after 20 weeks of gestation.
Proteinuria was defined as $300 mg per 24-h urine collection,
$2+ protein on voided urine sample, $1+ protein on catheterized
urine specimen, or a protein-creatinine ratio of $0.3. Women
with uncomplicated pregnancy were normotensive and without
proteinuria throughout gestation, and delivered healthy babies. All
patients were non-smokers by self-report, and were without clinical
history of preexisting renal, vascular, or metabolic disease.
The maternal peripheral venous blood was withdrawn into
sterile collection tubes. The blood samples were incubated at room
temperature for 30 min and then centrifuged for 20 min at
2,0006g at RT. The serum was stored at 280uC for later use.
Once all samples were acquired, four separate pools of serum were
created (combining n= 6 patient samples/pool), namely primip-
arous uncomplicated pregnancy, multiparous uncomplicated
pregnancy, primiparous preeclampsia (PE) and multiparous PE
pools. Both the individual serum samples and the serum pools
were used for the ECFC functional assays.
Culture of Placental Villous Explants and Preparation of
Conditioned Medium
The clinical and demographic data for women who provided
both placentas and umbilical cord blood for this study are
presented in Table 2. Placental villous explant preparation and
culture was carried out according to published protocols with some
modifications at Hannover Medical School [20]. Briefly, placentas
from 16 uncomplicated, healthy pregnancies delivered by vaginal
or Cesarean section were obtained within 10 min of delivery. All
of these patients but two had singleton pregnancies. Biopsies were
excised from the maternal side of the placenta, after removal of the
decidua, midline between the central and lateral part of the
placental edge. The tissue was immediately transported to the
laboratory in ice-cold phosphate buffered saline (PBS) containing
2% penicillin/streptomycin. After rinsing the placental pieces in
PBS to wash out blood, large vessels and decidua were removed by
blunt dissection. Placental villous explants (1–2 mg each in size)
were dissected and used for experiments under different oxygen
conditions. An average of 50 mg of finely dissected villous tissue
was placed into each well of a 12-well plate containing 1.5 ml of
Medium 199 (Sigma-Aldrich, St- Louis, MO, USA) supplemented
with 2% Fetal Bovine Serum (FBS, Biochrom, Berlin, Deutsch-
land) and 1% penicillin–streptomycin (Biochrom, Berlin, Deutsch-
land). The plates were incubated under controlled oxygen
conditions (2% O2, 8% O2 and 21% O2) in three separate
incubator chambers (Xvivo, Biospherix Inc., USA) at 37uC, 5%
CO2 for 48 h. The CM was centrifuged (3,200 rpm, 4uC, 5 min)
and the cell-free supernatants were frozen at 280uC for later use.
For the experiments the CM were pooled according the oxygen
conditions and stored in aliquots at 280uC. As control, M199
medium supplemented with 2% FBS, 1% penicillin–streptomycin
(non-conditioned medium, NCM) was employed in the same ratio
as conditioned medium (CM).
ECFC Cell Isolation and Culture
Umbilical cord blood was collected into sterile Vacutainer tubes
containing ethylenediaminetetraacetic acid (EDTA) immediately
after delivery. Within 2 h of collection, the blood was centrifuged
at 400 g for 10 min at room temperature, and the plasma was
removed and replaced with plasma replacement buffer (PBS
containing EDTA [7.4 g in 1 l, Sigma Aldrich, Steinheim,
Germany] and 1% penicillin/streptomycin). The umbilical cord
blood/plasma replacement buffer mixture was then doubled in
volume by addition of an equal amount of isolation buffer (PBS,
2% FBS, 1% penicillin/streptomycin). This blood suspension was
layered on Ficoll Plus (GE Healthcare, Buckinghamshire,
England) and subjected to density gradient centrifugation (400 g,
40 min) with brake in the off position. The mononuclear cell layer
was collected and 50 million cells per well seeded into collagen-1-
coated 6-well plates (BD Biosciences, Heidelberg, Germany) using
Endothelial Basal Medium 2 (EBM-2, Lonza, Walkersville, MD,
USA), supplemented with EGM-2 Single Quot Kit (Lonza) in
supplier-recommended concentrations of human recombinant
epidermal growth factor, fibroblast growth factor, VEGF, ascorbic
acid, hydrocortisone, recombinant insulin-like growth factor)
containing 10% FBS and 1% penicillin/streptomycin. After 10–
21 days (range) of cultivation ECFCs appeared as adherent single
layers of cobblestone shaped, late outgrowth cells that formed
colonies (.50 cells). Individual colonies were harvested using
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cloning rings and replated separately in tissue culture flasks.
ECFCs were used at 80–90% confluence and between passages 4–
7 in experiments.
Phenotyping of ECFCs
The endothelial phenotype of the isolated blood cells was
confirmed by flow cytometry using VEGFR-2, CD31, CD34,
CD133 and CD45 as well as appropriate isotype controls, and by
using fluorescein isothiocyanate-labeled Ulex europaeus agglutinin
I (lectin; Sigma-Aldrich, Steinheim, Germany) for cell surface
staining, and acetylated low-density lipoprotein (Dil-Ac-LDL;
Biomedical Technologies, Stroughton, MA) to confirm cellular
uptake of Dil-Ac-LDL, as described previously in detail [19].
RNA Interference
RNA interference experiments were performed with siRNA for
VDR (Silencer Validated siRNA VDR, Life Technologies,
AM51331) and scrambled siRNA (Silencer Negative Control
No. 1 siRNA, Life Technologies, Carlsbad, USA) using Dharma-
fect 1 (Dharmacon, Lafayette, CO, USA), according to the
manufacturer’s instructions. Briefly, cells were plated and then
transfected at 80–90% confluence with 50 nM siRNA for 24 h.
The efficiency of siRNA transfection was tested using fluorescein-
conjugated control siRNA.
Table 1. Clinical and demographic data of patients who provided maternal blood samples.
Variable Uncomplicated pregnancy (n =12)
Preeclampsia
(n =12) P value
Maternal age (y) 25.967.0 29.268.3 NS
Gestational age at time of blood sampling (wks) 36.564.2 37.462.3 NS
Gestational age at delivery (wks) 36.664.1 37.562.3 NS
Multiparous- n (%) 6 (50%) 6 (50%) NS
Maternal pre-pregnancy BMI (kg/m2) 25.565.3 26.565.8 NS
Gestational SBP, pre-delivery (mm Hg) 120613 151617 ,0.001
Gestational SBP before 20 week gestation (mm Hg)* 11868 10769 ,0.01
Gestational DBP, pre-delivery (mm Hg) 7167 9169 ,0.001
Gestational DBP before 20 week gestation (mm Hg)* 7165 6969 NS
Birth weight (g) 28776930 26486689 NS
Birth weight percentile 52.4623.6 33.6630.7 NS
Birth weight percentile ,10th- n (%) 0 (0%) 2 (17%) NS
Caesarean delivery- n (%) 3 (25%) 4 (33%) NS
Labor at the time of blood sampling- n (%) 8 (67%) 6 (50%) NS
Maternal Race, Black – n (%) 4 (33%) 4 (33%) NS
Baby gender, male- n (%) 7 (58%) 3 (25%) NS
BMI, body mass index; DBP, SBP, diastolic and systolic blood pressure (average of last three measurements). Data are given as mean 6 SD or number (percentage).
*Early BP values were not available for 3 preeclampsia patients; all patients were normotensive postpartum.
doi:10.1371/journal.pone.0098527.t001
Table 2. Clinical and demographic data for the uncomplicated pregnant women who provided placental samples for villous
explant culture (data are mean +/2 SD).
Variable
n 16
Maternal Age (y) 3363.3
Multiparous – n (%) 9 (56%)
Maternal prepregnancy BMI (kg/m2) 27.166
Gestational SBP, pre-delivery (mmHg) 119.9613.5
Gestational DBP, pre-delivery (mmHg) 68.6611.3
Birth Weight (g) 3437.56735
Gestational Age (weeks) 38.861.3
Caesarean delivery- n (%) 9 (56%)
Labor with delivery –n (%) 7 (44%)
Smoking- n (%) 0 (0%)
doi:10.1371/journal.pone.0098527.t002
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In vitro Angiogenesis Assay
We used an in vitro angiogenesis assay (endothelial tubule
formation in Matrigel) as a test of ECFC function. 17,000 ECFCs/
well were seeded into 96 well plates, each well pre-coated with
50 ml growth factor- reduced Matrigel (BD Biosciences, Bedford,
MA). The ECFCs in Matrigel assay were exposed to pooled sera
from normal pregnancy or preeclampsia patients (5% v/v
concentration in EBM-2). We also tested the effect of the
individual (non-pooled) serum samples (uncomplicated control
versus preeclampsia; n = 12 samples each) at 5% v/v. The
experiments were performed in the presence and absence of
10 nM 1,25(OH)2 vitamin D3 [21,22]. In separate experiments,
conditioned media (CM) or non-conditioned media (NCM) were
added at 25% v/v concentration in EBM-2. After 14 h of
incubation, digital images were obtained at 2.5x magnification.
The total length of tubules per visual field (per well) was
determined with Image J software. All experiments were done in
triplicate wells from which values were averaged (n= number of
experiments).
Cell Migration Assay
To analyze ECFC migratory ability, ECFCs were pre-treated
with EBM-2+2% v/v FBS, with or without 10 nM 1,25(OH)2
vitamin D3 for 24 h. The confluent ECFC monolayers were
scratched using a sterile P200 pipette tip to produce a lane free of
cells as described before [23]. Pooled sera from normal or
preeclamptic patients was added at 5% v/v concentration. CM or
NCM were added at 50% v/v concentration. The sera and media
experiments were performed in the presence or absence of 10 nM
1,25(OH)2 vitamin D3. Light microscopic images were obtained
immediately after the scratch (T0) and at the end of the experiment
(18 h for CM; 8 h for serum). Migration into the scratch wound
was analysed using Image J software and calculated as percentage
of wound closure (percentage of original area that became
occupied by cells by migration into the wound area). All
experiments were done in quadruplicate wells from which values
were averaged.
VDR Silencing and VEGF Pathway Inhibition
The VDR was blocked with the VDR antagonist pyridoxal-5-
phosphate (0.5 mM, Cell Signaling/New England Biolabs,
Frankfurt am Main, Germany) or down-regulated by transfection
with validated VDR siRNA. We and others have shown that
vitamin D has a stimulatory effect on the VEGF pathway, which is
important for angiogenesis and repair of vessels [19,24]. There-
fore, we also inhibited the VEGF pathway by SU5416 (0.5 mM,
Sigma Aldrich, Steinheim, Germany).
Vitamin D3 Measurement in Patient Serum
25(OH) Vitamin D concentrations in the individual maternal
serum samples were determined using a LIAISON 25(OH)
Vitamin D TOTAL Assay (DiaSorin Inc., USA), as per the
manufacturers recommendations, at Hannover Medical School.
Statistical Analysis
Statistical analysis was performed after testing for normality
distribution by Kolmogorov-Smirnov-test. One-way analysis of
variance, Kruskal-Wallis test, unpaired t-test, Mann-Whitney U or
Wilcoxon-signed rank test were used as appropriate (Prism 4
software package, GraphPad Software Inc., La Jolla, CA).
Demographic data are expressed as means and standard deviation
(SD) and experimental data as means and standard error (SEM),
with P,0.05 considered as statistically significant.
Results
Patient Demographics
Maternal age, pre-pregnancy body-mass index, race and parity
were not statistically different between the preeclampsia cases and
uncomplicated pregnancy controls who provided serum samples
(Table 1). By definition, women with preeclampsia had signifi-
cantly higher systolic and diastolic blood pressures at delivery
compared to controls. The gestational age at the time of
venipuncture was not significantly different between the groups.
Table 2 shows the characteristics of the uncomplicated pregnancy
patients that contributed their placentas for villous explant culture.
Two of 16 were twin pregnancies.
In vitro Angiogenesis
Figures 1 A–B show the effects of serum from preeclampsia
patients compared to serum from uncomplicated controls on
capillary-tube formation by ECFCs, in which data from the
primiparous serum pool and the multiparous serum pool are
combined for each pregnancy outcome group. Here, tubule
lengths are expressed as percent relative to the value (set at 100%)
obtained in the presence of uncomplicated pregnancy pooled sera
(control without supplemental vitamin D). Tubule formation was
significantly less in the presence of preeclampsia serum (8463%;
P,0.001; n = 15 experiments) compared to uncomplicated preg-
nancy serum (Figure 1A). As shown in Figure S1, tubule
assemblage was significantly impaired by either the primiparous
preeclampsia pooled sera compared to primiparous control pooled
sera (9062.5%; P= 0.01; n= 6 experiments), or multiparous
preeclampsia pooled sera compared to multiparous control pooled
sera (7964.5%; P= 0.01; n= 9 experiments).
We tested, the impact of 1,25(OH)2 vitamin D3 on tubule
formation when in the simultaneous presence of pooled control or
pooled preeclampsia sera. Vitamin D at 1 nM and 10 nM
significantly increased total tubule length in the preeclamptic
and control serum-treated groups (Figure 1A and Figure S1). As
shown in Figure 1A, in which data from primiparous and
multiparous sera are combined, 1 nM and 10 nM 1,25(OH)2
vitamin D3 stimulated tubule formation in the presence of both
control sera (1 nM: 11464%; P=0.01; n= 15; 10 nM: 11464%;
P= 0.01; n= 12) and preeclampsia sera (1 nM: 12464%; P=0.01;
n = 15; 10 nM: 12364%; P,0.001; n = 12) such that the effects of
preeclampsia vs. control sera were no longer significantly different
(p.0.05).
We tested the effect of the individual (non-pooled) serum
samples (uncomplicated control versus preeclampsia; n = 12
samples each) using one ECFC cell line derived from a control
pregnancy and found comparable results. With control and
preeclampsia serum samples tested as tandem pairs and matched
for BMI, gestational and maternal age, 11 out of 12 serum samples
from preeclamptic women lead to reduced tubule lengths
compared to the control serum. In summary, serum of
preeclamptic patients impaired angiogenetic capacity compared
to control serum (8764%; P= 0.01; n = 12). Relative to tubule
formation in the presence of control pregnancy serum alone
(100%), 1,25(OH)2 vitamin D3 increased tubule formation (1 nM:
10664%; P= 0.02; n = 12; 10 nM: 11063%; P=0.01; n= 12).
Relative to tubule formation in the presence of preeclampsia
serum alone (100%), 1,25(OH)2 vitamin D3 likewise increased
tubule formation (1 nM: 10964%; P= 0.03; n = 12; 10 nM:
11464%; P= 0.01; n= 12). In the presence of vitamin D
(10 nM), preeclampsia vs. control patient sera no longer had
significantly different effects (P.0.05).
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Figures 2 A–C display the results of treatment of ECFCs with
placental villous explant CM (from cultures under 2%, 8% and
21% O2) compared to NCM. The effect of 1,25(OH)2 vitamin D3
is illustrated within the figures. ECFCs from uncomplicated
pregnancies were used, and total tubule length was determined in
the in vitro Matrigel angiogenesis model. There was no difference
in tubule formation between the 2% O2, 8% O2 and 21% O2 CM
(Figure 2 A). However, a reduction of angiogenesis with CM from
2% O2 villous explant culture was observed compared to NCM
(8167.4%; P= 0.03, n= 9). Vitamin D did not exhibit a significant
effect under these conditions.
Migration
As shown in Figure 3 A–C we found a reduction in migration of
ECFCs when in the presence of primiparous (9063%; P=0.02;
n = 6 experiments) or multiparous (9266%; P=0.03; n = 12
experiments) preeclampsia pooled sera compared to the corre-
sponding control pooled sera. Combining data from primi- and
Figure 1. Effect of uncomplicated pregnancy (control) sera and preeclampsia (PE) sera, and 1,25(OH)2 vitamin D3, on capillary-tube
formation by ECFCs in a Matrigel assay. ECFCs were cultured in endothelial basal medium (EBM) +5% v/v sera. Capillary-tube formation (average
total tubule length per microscopic field) was analyzed after 14 h by visual microscopy at 2.5 magnification (A). Data are expressed as percentage of
the control in the absence of vitamin D. Results represent mean values of total tubule length 6 SEM of at least 6 independent experiments; *P,0.05
vs. control; Horizontal bars with asterisk (2*2): P,0.05, preeclampsia sera without vitamin D vs. preeclampsia sera with vitamin D. (B) Representative
photomicrographs of ECFCs after incubation in Matrigel with EBM+5% v/v patient sera. Scale bar represents 750 mm.
doi:10.1371/journal.pone.0098527.g001
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multiparous patient samples, the negative effect of preeclampsia
pooled sera on ECFC migration remained significant (9264%;
P=0.01; n = 18).
As shown in Figure 3, the simultaneous addition of 1,25(OH)2
vitamin D3 increased the migrative abilities of ECFCs into the
scratch wound during incubation with pooled primiparous (1 nM:
114610%; P=0.03; n= 6; 10 nM: 11566%; P= 0.053; n= 6) or
multiparous (1 nM: 12065%; P=0.01; n= 12; 10 nM: 11464%;
P=0.01; n= 9) preeclampsia pooled sera (100%). We found a
stimulating effect of 10 nM 1,25(OH)2 vitamin D3 in the presence
of pooled sera from primiparous controls (1 nM: 10965%;
P=0.11; n = 6; 10 nM: 117610%; P= 0.03; n= 6) and stimulat-
ing effect of both 1 nM and 10 nM 1,25(OH)2 vitamin D3 in the
presence of pooled sera from multiparous controls (1 nM:
12064%; P,0.001; n= 12; 10 nM: 12066%; P= 0.03; n = 9).
When combining data from primi- and multiparous patient pools,
1,25(OH)2 vitamin D3 enhanced ECFC migration both in the
presence of control sera (1 nM: 11663%; p,0.001; n= 18;
10 nM: 11965%; P= 0.01; n= 15) and preeclampsia sera (1 nM:
11865%; P= 0.01; n= 18; 10 nM: 11563%; P,0.001; n = 15),
such that the differential effects of case vs. control sera remained
significant. ECFC migration in the presence of preeclampsia sera
+ vitamin D was not different from uncomplicated pregnancy sera
alone.
Placental villous explant CM derived from 2% O2 incubations
(86.167.2%, P= 0.02, n= 9) and 21% O2 incubations (8664.1%,
P= 0.02, n = 10) significantly reduced ECFC migration, when
compared to CM from 8% O2 (Figure 4 A). Compared to NCM,
explant CM from 2% O2 (7467%; P=0.005) and 21% O2
(7167.1%, P=0.003, n= 10), but not 8% O2, impaired ECFC
migration (Figure 4 B). Compared to absence of vitamin D,
1,25(OH)2 vitamin D3 improved endothelial cell migration in 2%
O2 CM (11064.4%, P= 0.046) and 21% O2 CM (12468.7%,
P= 0.02), but not significantly in 8% O2, (11367.9%, P= 0.15)
(n = 10). 1,25(OH)2 vitamin D3 normalized the negative effects of
2% O2 CM (9565.5%, P= 0.36) and 21% O2 CM (10869.9%,
P= 0.46) when compared to 8% O2 CM (data not shown). ECFCs
treated with 2%, 8% or 21% CM and vitamin D were also not
statistically different compared to NCM (P.0.05), (Figures 4 B
and C).
VDR Blocking and Inhibition of VEGF Pathway
The effects of VDR and VEGF inhibitors (P5P and SU4516,
respectively) on ECFC tubule formation were tested in the
presence of pooled control sera (Figure 5 A) or pooled
Figure 2. Effect of villous explant conditioned medium (2% O2, 8% O2, 21% O2 CM) and 1,25(OH)2 vitamin D3 on capillary-tube
formation in a Matrigel assay. ECFCs were cultured in endothelial basal medium (EBM) +25% CM (A–C). Capillary-tube formation (average total
tubule length per microscopic field) was analyzed after 14 h by visual microscopy at 2.5 magnification. Data are expressed as percentage of control
(2A: 8% O2 CM+0 nM vitamin D3; 2B: NCM+0 nM vitamin D3). Results represent mean values of total tubule length 6 SEM of at least 9 independent
experiments; *P,0.05 vs. control, C: Representative photomicrographs of ECFCs after plating on Matrigel cultured in EBM+25% v/v CM. Scale bar
represents 750 mm.
doi:10.1371/journal.pone.0098527.g002
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preeclampsia sera (Figure 5 B). P5P inhibited tubule formation
(percent relative to control sera alone: 7168.9%; P=0.045; n= 4;
percent relative to preeclampsia sera alone: 7466.8%; P= 0.02;
n = 5). SU5416 similarly inhibited tubule formation (percent
relative to control sera alone: 36613.5%; P= 0.02; n= 4; percent
relative to preeclampsia sera alone: 48611.9%; P= 0.02; n = 4).
Silencing of the VDR also impaired tubule formation (percent
relative to control sera alone: 5967.2%; P= 0.01; n= 4; percent
relative to preeclampsia sera alone: 7862.6%; P= 0.01; n = 4),
(data compared to non-silenced control ECFCs). Non-targeting
siRNA transfected ECFCs were used as an internal control. Total
ECFC tubule lengths were not affected by the non-targeting
siRNA (percent relative to control sera alone: 9861.8%; P= 0.27;
n = 4; percent relative to preeclampsia sera alone: 10464.8%;
P=0.5; n= 4). Vitamin D significantly increased tubule formation
in the presence of uncomplicated pregnancy (Figure 5 A) or
preeclampsia sera (Figure 5 B) (control = sera without VDR or
VEGF inhibitors). Vitamin D significantly reversed the negative
effects of VDR blockade (P5P) on tubule formation, and non-
significantly attenuated the negative effects of VEGF blockade
(SU5416), but had no effect after VDR silencing (Figure 5 A and
B).
The impact of VDR or VEGF pathway inhibition on ECFC
migration was tested in the presence of 2% O2 incubation-derived
villous explant culture CM (Figure 5 C). A significant reduction of
scratch wound closure was observed in the presence of P5P
(7864.9%; P= 0.004, n = 7) and SU5416 (8765.3%; P=0.04,
n = 8). Vitamin D had a rescuing effect on ECFC migration after
blocking the VDR (P5P+VD: 11164.4%; P= 0.049, n= 7), but
not the VEGF pathway (SU5416+ VD: 10464.6%; P=0.46,
n = 8).
Maternal Vitamin D Status
None of the patients had normal (replete) vitamin D levels (.
30 ng/ml [25]). More women with preeclampsia (PE: 7/12, NP:
3/12) showed severe vitamin D deficiency (,10 ng/ml), although
not significantly so (P= 0.21). There was no significant relationship
Figure 3. Effect of uncomplicated pregnancy (control) sera and preeclampsia (PE) sera from primiparous (A) and multiparous (B)
women, and 1,25(OH)2 vitamin D3, on ECFCmigration. ECFCs of uncomplicated pregnancies were cultured in endothelial basal medium (EBM)
+5% v/v patient sera and treated with or without 1 nM or 10 nM 1,25(OH)2 vitamin D3. The migration of ECFCs into the scratch wound was assessed.
ECFC migration was reduced in the presence of preeclampsia sera compared to control sera of primiparous (A) and multiparous (B) women. Vitamin
D restored or improved migrative capacity. Results represent mean 6 SEM percent wound filling of at least 6 independent experiments, *P,0.05 vs.
control; Horizontal bars with asterisk (2*2): P,0.05, preeclampsia sera without vitamin D vs. preeclampsia sera with vitamin D. C: Representative
images of ECFC monolayers with scratch wounds at 0 h (a, c) and 8 h (b, d) of incubation. Scale bar represents 750 mm.
doi:10.1371/journal.pone.0098527.g003
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between maternal serum vitamin D concentration and fetal ECFC
response to the patient serum in cell culture (P= 0.45).
Discussion
One major finding of this study is that ECFCs exhibited
markedly decreased tubule formation and migration in vitro in
response to serum from women with preeclampsia compared to
serum from women with uncomplicated pregnancies. Both pooled
serum and individual patient serum samples from women with
preeclampsia exhibited these inhibitory effects. A second major
finding is that suppression of ECFC migration was also observed in
response to conditioned media collected from placental villous
explants cultured under aberrant oxygen conditions [2% O2
(‘‘hypoxic’’) or 21% (‘‘hyperoxic’’)] when compared to either 8%
O2 (‘‘normoxic’’) or non-conditioned media. These inhibitory
effects on ECFC behaviors were substantially reversed by
exogenous administration of vitamin D in the physiologic range.
VDR signaling antagonism (pyridoxal-5-phosphate) reduced
ECFC tubule formation and migration in a fashion partially
reversed by exogenous vitamin D, likely related to competition for
binding to the vitamin D receptor (VDR).
During the first weeks of normal pregnancy, the placental
environment is hypoxic (,2% O2), but the oxygen level rises up to
6–8% O2 around 12 weeks of gestation, which is considered
physiologic during the second and third trimester of pregnancy
[26]. At term, 6–8% O2 is thought to represent ‘‘normoxia’’ and
1–2% O2 ‘‘hypoxia’’ for villous tissue [27]. In this study 2% O2
was used as hypoxic, 8% O2 as normoxic and 21% O2 as
‘‘hyperoxic’’ conditions as in previous studies [28,29]. We
speculate that our findings of reduced ECFC functional capacities
during incubation with both low (2%) and high (21%) O2 might
relate to increased generation of anti-angiogenic/pathogenic
factors under these conditions compared to 8% O2 explant
culture conditions. Both hypoxia, especially with fluctuations in
oxygen concentration, and hyperoxia can result in placental
oxidative stress with release of inflammatory cytokines and/or
anti-angiogenic factors [30]. In preeclampsia, low or fluctuating
oxygen levels might persist due to impaired utero-placental blood
flow and lead to disturbances in the placenta. The associated
increased release of placenta-derived factors is believed to
contribute to the disturbed maternal endothelial homeostasis
[1,31]. The nature/effects of the circulating placental factors
remain intensively investigated [31].
Figure 4. Effect of villous explant conditioned medium (2% O2, 8% O2, 21% O2 CM) and 1,25(OH)2 vitamin D3 on ECFC migration.
ECFCs of uncomplicated pregnancies were cultured in endothelial basal medium (EBM) +50% v/v CM and treated without (vehicle control) or with
10 nM 1,25(OH)2 vitamin D3. The migration of ECFCs into the scratch wound was assessed. ECFC migration was lower in 2% O2 and 21% O2 villous
explant CM compared to 8% O2 CM (A) and NCM (B). Vitamin D restored migrative capacity. Results represent mean 6 SEM percent wound filling,
N = 10, *P,0.05 vs. control (0 nM vitamin D). C: Representative images of ECFC monolayers with scratch wounds at 0 h and 18 h of incubation. Scale
bar represents 750 mm.
doi:10.1371/journal.pone.0098527.g004
Vitamin D Reverses Preeclampsia Serum-Induced EPC Dysfunction
PLOS ONE | www.plosone.org 8 June 2014 | Volume 9 | Issue 6 | e98527
Previously, metabolic footprinting of placental villous explant
conditioned culture media identified differences as a function of
normoxic, hypoxic and hyperoxic incubation conditions [32].
Uncomplicated pregnancy villous tissue incubated under hypoxic
conditions, and preeclampsia villous tissue incubated under
normoxic conditions produced very similar metabolic footprints
[32]. Others have reported that endothelial cell proliferation was
reduced by plasma, but not serum, from preeclamptic women
[33]. This is in contrast to our study were we show a significant
negative effect of preeclampsia serum on ECFCs in vitro.
Vitamin D deficiency has been linked to an approximate 5-fold
increased risk for the development of preeclampsia [14–16]. The
vitamin D receptor (VDR) is expressed in human placenta,
endothelial cells and (we have shown) in cord ECFCs [19,34,35].
Potentially relevant to preeclampsia, vitamin D regulates key
target genes associated with implantation, trophoblast invasion
and anti-inflammatory responses in maternal decidua and fetal
trophoblast [36–38]. Vitamin D regulates angiogenesis through
direct effects on VEGF gene transcription [19,24,39]. Our
published data show a stimulating and VEGF-dependent effect
of physiologic concentrations of vitamin D on fetal (cord blood)
ECFC function [19]. We now demonstrate a stimulating effect of
vitamin D on ECFC migration and capillary-tube formation,
overcoming adverse effects of serum from preeclamptic women.
Vitamin D also enhanced ECFC function after treatment with
hypoxic or hyperoxic villous CM. These effects were dependent on
VDR activation as indicated by silencing and blocking the
receptor. Here we also confirmed that blocking of the VEGF
pathway impairs ECFC function. However, vitamin D did not
substantially restore the inhibiting effect of the VEGF pathway
inhibitor SU5416 in the presence of patient sera or villous CM.
Vitamin D was able to rescue the angiogenic deficits caused by
preeclampsia sera (Figure 1), but not those caused by 2% oxygen
conditioned media (Figure 2). Chronic hypoxia might not exactly
model the effects of fluctuations (hypoxia-reoxygenation) thought
to frequently occur with preeclampsia [30]. The milieu in
maternal serum may be more complex, with levels of maternally
derived factors differing by pregnancy outcome group. Alterna-
tively, concentrations of anti-angiogenic factors may be higher in
placenta CM compared to maternal serum. The magnitude of
Figure 5. Effect of 1,25(OH)2 vitamin D3 and the inhibitors pyridoxal-5-phosphate, SU5416 and vitamin D receptor (VDR) small
interfering (si)RNA on ECFC capillary-tube formation or migration. ECFCs were incubated with uncomplicated pregnancy sera (A) or
preeclampsia sera (B) or 2% O2 villous explant conditioned medium (C), and in the presence or absence (control) of 0.5 mM pyridoxal-5-phophate,
0.5 mM SU5416, VDR siRNA, or non-targeting (scrambled) siRNA. The effects of each of these exposures were additionally examined both in the
absence (vehicle) or presence of 10 nM 1,25(OH)2 vitamin D3. Total tubule lengths (A, B) or migration (C) were determined and expressed as percent
relative to control. Results represent mean 6 SEM of at least 4 independent experiments. *P,0.05 compared to control. Other significant differences
(P,0.05) are indicated by the horizontal bars.
doi:10.1371/journal.pone.0098527.g005
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change (increase) in tubule formation effected by vitamin D was
greater when in the presence of preeclampsia sera compared to
uncomplicated pregnancy sera, such that tubule formation became
equalized (Figure 1). This differential response to vitamin D
according to sera was not observed with migration. The reason for
this non-uniformity of response remains unclear.
Preeclampsia is a risk factor for cardiovascular events in the
mother and offspring later in life [31,40]. Potentially germane to
this, early life vitamin D deficiency in a rat model was associated
with endothelial dysfunction and elevated blood pressure in the
offspring [41], and a study in mice found vitamin D deficiency in
pregnancy to lead to maternal hypertension and altered placental
and fetal development [42]. These in vivo data are consistent with
the hypothesis that vitamin D insufficiency predisposes pregnant
women and their offspring to disturbed endothelial homeostasis.
ECFCs, a sub-population of EPCs, posses the unique ability for
vasculogenesis – the de novo formation of blood vessels from
progenitor cells. The few studies of fetal ECFCs and pregnancy
complications describe a reduction in fetal ECFC numbers and
colony formation in diabetic pregnancies or pregnancies with
growth restricted infants [43,44]. Most interestingly recent data
point to the ability of human fetal ECFCs, but not human fetal
endothelial cells, to transmigrate to the maternal bloodstream and
then home to locations of maternal uterine vasculogenesis [13].
Our data suggest that fetal ECFCs respond to pathogenic stimuli
by impairment of functional activities and that these can be
reversed by vitamin D. A logical future step would be to
accumulate conditioned media from gestational age-matched
preeclampsia and uncomplicated pregnancy villous placenta for
comparison. The extent to which villous fragments in explant
culture accurately retain their in vivo phenotype is uncertain.
However, it was previously reported that, compared to condi-
tioned media from uncomplicated, term pregnancy villous
explants, conditioned media from preeclampsia placental villous
explants suppress in vitro tubule formation and migration of human
umbilical vein endothelial cells (HUVEC) in culture [45]. These
effects appeared to be attributable to increased secretion of the
soluble receptor, soluble vascular endothelial growth factor
receptor-1 (sVEGFR-1, also known as sFLT1), by preeclampsia
explants, consistent with the elevated placental secretion of sFLT1
in vivo [5].
Several reports indicate that 1,25(OH)2 vitamin D either
decreases or has no effect on endothelial cell proliferation or
angiogenesis in vivo or in vitro [46,47]. The divergent results might
reflect heterogeneity among endothelial cell subtypes. ECFCs
reportedly differ from mature human umbilical vein endothelial
cells (HUVEC) or human umbilical artery endothelial cells in the
expression of differentiation-related surface markers, proliferation
rates, or telomerase activities [48]. However the reason for the
apparent distinct proangiogenic effects of vitamin D on ECFCs is
presently unclear. To speculate, vitamin D might upregulate the
release of factors by progenitor cells that, in turn, stimulate
angiogenic behaviors in autocrine fashion. Hematopoietic endo-
thelial progenitor cells, a more prevalent circulating cell type
compared to ECFCs, express functional vitamin D receptors.
Conditioned media from vitamin D treated hematopoietic
endothelial progenitors increased tubule networks of human aortic
endothelial cells in Matrigel in vitro, whereas vitamin D alone did
not [49].
To our knowledge this is the first study to investigate the effect
of placenta-derived factors on ECFC function and to explore a
putative positive role of vitamin D for restoring endothelial
function in this context. Effective preventive or therapeutic
strategies for preeclampsia do not exist to date. It is plausible
that ensuring vitamin D sufficiency before and during pregnancy
will reduce endothelial dysfunction and disease development in
mother and offspring.
Supporting Information
Figure S1 Effect of uncomplicated pregnancy (control)
pooled sera and preeclampsia (PE) pooled sera from
primiparous (A) and multiparous (B) women, and
1,25(OH)2 vitamin D3, on capillary-tube formation by
ECFCs in a Matrigel assay. ECFCs were cultured in
endothelial basal medium (EBM) +5% v/v sera. Capillary-tube
formation (average total tubule length per microscopic field) was
analyzed after 14 h by visual microscopy at 25x magnification.
Data are expressed as percentage of the control in the absence of
vitamin D. Results represent mean values of total tubule length 6
SEM of at least 6 independent experiments; *P,0.05 vs. control;
Horizontal bars with asterisk (2*2): P,0.05, preeclampsia serum
without vitamin D vs. preeclampsia serum with vitamin D.
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